CAP

CAP Statement in Support of the Protecting Medicare and American Farmers from Sequester Cuts Act

Retrieved on: 
Tuesday, December 7, 2021
Managed Care, Other Health, Professional Services, Consumer, Healthcare Reform, Hospitals, Public Policy, Other Policy Issues, Insurance, Seniors, Congressional News, Views, Health, Public Policy, Government, Congress, Physician, Pathology, List of pathologists, Medicare, House, College of American Pathologists, Senate, Patient, COVID, College, Farmer, American Farmer, Annual report, CAP, Marie Cassidy, Investment, Pharmaceutical industry, Health insurance

The College of American Pathologists President Emily E. Volk, MD, FCAP, released the following statement in support and urges quick passage of the Protecting Medicare and American Farmers from Sequester Cuts Act.

Key Points: 
  • The College of American Pathologists President Emily E. Volk, MD, FCAP, released the following statement in support and urges quick passage of the Protecting Medicare and American Farmers from Sequester Cuts Act.
  • :
    The College of American Pathologists (CAP) supports the introduction and swift passage of the Protecting Medicare and American Farmers from Sequester Cuts Act that would mitigate the impact of various payment cuts affecting pathologists and the services they provide to Americans seniors beginning in January of 2022.
  • The effect of these cuts will further exacerbate health care disparities that exist in rural and urban areas.
  • As a 501(c)(6) membership organization, the CAP is the only entity representing pathologists with unrestricted advocacy capability and a political action committee, PathPAC.

Predictive Health Diagnostics Company's PULS Cardiac Test Plays Key Role in Detecting Vascular Inflammation Common After Receiving COVID-19 Vaccines

Retrieved on: 
Tuesday, December 7, 2021
Genetics, Physician, Probability, ACS, Twitter, Risk, Good, Company, Forward-looking statement, PHDC, Health, List of pathologists, Thrombosis, Technology, American Heart Association, AHA, Pfizer, Inflammation, Cardiomyopathy, Biochemistry, RNA transfection, View, Patient, Vaccine, Phenotype, Industry, Good laboratory practice, Endothelium, Vaccination, Diabetes, College, Health care, Science, Acute coronary syndrome, GMP, GLP, Multimedia, Clinical Laboratory, COVID-19, ISO, Good manufacturing practice, College of American Pathologists, Proteomics, LinkedIn, CLIA, Stroke, CAP, Obesity, Degenerative disease, Pharmaceutical industry, Medical device

The company commented on the role of its PULS Cardiac Test in identifying vascular inflammation and cardiac risks in patients after receiving double-dose COVID-19 vaccines.

Key Points: 
  • The company commented on the role of its PULS Cardiac Test in identifying vascular inflammation and cardiac risks in patients after receiving double-dose COVID-19 vaccines.
  • In studies of COVID-19 vaccinated patients, significant increases in PULS Test vascular inflammation markers leading to an increased risk of acute coronary syndrome were revealed in most subjects.
  • The study author concluded that "mRNA [vaccines] increase vascular inflammation of the endothelium and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination."
  • The PULS Cardiac Test diagnoses vascular inflammation and is used to generate a risk of a patient experiencing a heart attack or stroke in the near future.

MAKO Medical Detects Three Cases of COVID-19 Omicron Variant in U.S.

Retrieved on: 
Tuesday, December 7, 2021
COVID-19 testing, N, Physician, Veterans Day, Thermo Fisher Scientific, Risk, PCR, RT, GLOBE, Workplace, Center, Technology, CDC, Omicron, K-12, Partnership, Centers for Disease Control and Prevention, American, Real-time, COVID-19, MAKO, Applied Biosystems, Veteran, Polymerase chain reaction, American City Business Journals, Hospital, CAP, Forbes, Severe acute respiratory syndrome coronavirus 2, Animal, Vaccine, Medical device, Pharmaceutical industry

The Centers for Disease Control and Prevention (CDC) confirmed the presence of the Omicron variant, also known as B.1.1.529, in the samples.

Key Points: 
  • The Centers for Disease Control and Prevention (CDC) confirmed the presence of the Omicron variant, also known as B.1.1.529, in the samples.
  • We hope our ability to expeditiously detect the Omicron variant will aid public health authorities in controlling the spread of the virus.
  • Earlier this year, MAKO Medical formed a comprehensive partnership with the CDC to provide next-generation sequencing of SARS-CoV-2.
  • As Arant explained, this technology allows MAKO Medical to single out samples that contain characteristics specific to the novel Omicron variant.

Sorrento Therapeutics’ Clinical Laboratory Receives Accreditation From the College of American Pathologists

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Pathology, Risk, READ, Forward-looking statement, Accreditation Committee of Cambodia, GLOBE, Medicare, Federation, Security (finance), Accreditation, Pain, Private Securities Litigation Reform Act, RTX, Patient, Therapy, Vaccine, Cancer, Osteoarthritis, College, Antibody, Certification, Trigeminal neuralgia, Trial of the century, Sciatica, Autoimmune disease, Medicaid, FDA, CLIA, National Accreditation Program for Rectal Cancer, SAN, Annual report, CAP, Marie Cassidy, TRPV1, Pharmaceutical industry, Generic drug

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrentos Clinical Laboratory, located in San Diego, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.

Key Points: 
  • SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrentos Clinical Laboratory, located in San Diego, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
  • Sorrentos clinical laboratory was advised of this national recognition and congratulated for the excellence of the services being provided.
  • Additionally, with the CLIA certification and CAP accreditation of its clinical laboratory, Sorrento has the capability to conduct timely clinical studies to support its product pipeline across all stages.
  • As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

Ingram Micro Cloud Launches Contracts Alliance Program to Support AWS Cloud Opportunities in the Public Sector

Retrieved on: 
Tuesday, December 7, 2021
Professional Services, Data Management, Small Business, Technology, Other Technology, Software, Internet, Cloud, Joint Ventures, AWS, Infrastructure as a service, Joint venture, JV, Growth, Contract, Amazon Web Services, Public, Pro-Mark, Partner, Program, Woman, Public sector, Small business, Solution, Communes of Burundi, CAP, Software as a service, Internet service provider, Professional Services, Data Management, Small Business, Technology, Other Technology, Software, Internet

Ingram Micro Cloud today announced the Contracts Alliance Program ( CAP ) for the US market, part of its broader Amazon Web Services (AWS) distribution offering, intended to provide faster, frictionless access to contracts within Ingram Micro Clouds developed federal, state, local and education portfolios.

Key Points: 
  • Ingram Micro Cloud today announced the Contracts Alliance Program ( CAP ) for the US market, part of its broader Amazon Web Services (AWS) distribution offering, intended to provide faster, frictionless access to contracts within Ingram Micro Clouds developed federal, state, local and education portfolios.
  • Ingram Micro Cloud is proud to introduce the Contracts Alliance Program, says Jason Singer, Director of Public Sector Cloud at Ingram Micro Cloud.
  • Partners can accelerate opportunities in the public sector by combining CAP with AWS programs including Think Big for Small Business (TBSB).
  • We have witnessed a flood of cloud opportunities over the past 12 months from the public sector, said Blake Kelly, Cloud Sales Manager at Strategic Communications.

Early Identification of Fatty Liver Using Echosens FibroScan Potentially Gives Payers Five-Year Gross Savings of $10+ Million, Confirmed by Independent Study

Retrieved on: 
Monday, December 6, 2021
Technology, Medical Devices, Diabetes, Fitness & Nutrition, Practice Management, Biotechnology, Managed Care, Health, Data Management, Patient, CAP, Ageing, Technology, Medicare, Population, NAFLD, The American Journal of Managed Care, Physician, Cedars-Sinai Medical Center, American Journal, ROI, Obesity, Risk, Elastography, Adult, Medicaid, FLD, Mortality, SBA, Chronic liver disease, Liver, Medical imaging

Published in the American Journal of Managed Care (AJMC), the study results concluded that early identification of patients with FLD through broad placement of VCTE/CAP devices offers cost savings to payers.

Key Points: 
  • Published in the American Journal of Managed Care (AJMC), the study results concluded that early identification of patients with FLD through broad placement of VCTE/CAP devices offers cost savings to payers.
  • Using patented VCTE and CAP, FibroScan is the first totally non-invasive device indicated for use as an aid in the clinical management of patients with liver disease.
  • The studys model was built to project medical cost savings driven by the device, relative to the net cost of the device.
  • FibroScan is supported by over 3,000 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

SomaLogic Announces Appointment of Steven Mermelstein as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions

Retrieved on: 
Thursday, December 2, 2021
Senior, CAP, Huron Consulting Group, US Foods, Forward-looking statement, Wasserstein Perella & Co., Form, SomaLogic, JPMorgan Chase, Mergers and acquisitions, SEC filing, Business, Strategic management, Corporation, Nasdaq, Twitter, GLOBE, Development, Government, M&A, Agilent Technologies, Dartmouth College, Clinical Laboratory, College, Integration, CLIA, NASDAQ, Food, Executive MBA Council, AB, Management, Risk management

BOULDER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Steve Mermelstein joined the company as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions (M&A).

Key Points: 
  • BOULDER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Steve Mermelstein joined the company as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions (M&A).
  • We are thrilled to welcome Steve to the SomaLogic team, said SomaLogic Chief Executive Officer Roy Smythe, M.D.
  • Steve has more than 25 years of experience providing strategic and corporate finance advice to senior management teams and boards of directors.
  • He has executed a broad range of corporate transactions, including M&A, growth equity investments, recapitalizations, out-licensing and joint ventures.

LIFESCALE ANALYTICS INC. (LSA), Releases Cyber Asset Platform (CAP)

Retrieved on: 
Tuesday, November 30, 2021
Cloud, Government, Insurance, CAP, Data analysis, Consultant, Data management, Awareness, LSA, IOT, Solution, ALL, Data science, View, Risk, Organization, Multimedia, Risk management

The Cyber Asset Platform (CAP) solution is a dashboard portal specifically engineered to consolidate cyber data across multiple sources, enabling visualization of cyber asset information, using a top-down view of assets across multiple divisions.

Key Points: 
  • The Cyber Asset Platform (CAP) solution is a dashboard portal specifically engineered to consolidate cyber data across multiple sources, enabling visualization of cyber asset information, using a top-down view of assets across multiple divisions.
  • Theo Laughner, LSA's Director of Engineering, summarizes: "Enterprise organizations frequently deploy many tools to assess the risk of their cyber assets.
  • Lifescale Analytics, Inc., based in Roseville, Minnesota, provides specialized expertise in data and analytics.
  • To learn more information about Lifescale Analytics visit www.lifescaleanalytics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/lifescale-analytics-inc-lsa-rel...

Omnitracs Announces New Managed Mobility Solution

Retrieved on: 
Tuesday, November 30, 2021
Compliance, Efficiency, CAP, Safety, LLC, Travel, Product management, Workflow, Tablet, Multimedia, Transport, Heavy equipment, Taxicab

DALLAS, Nov. 30, 2021 /PRNewswire/ -- Omnitracs, LLC , a Solera company, today announced a new all-in-one fully configured mobile device solution for Omnitracs One.

Key Points: 
  • DALLAS, Nov. 30, 2021 /PRNewswire/ -- Omnitracs, LLC , a Solera company, today announced a new all-in-one fully configured mobile device solution for Omnitracs One.
  • The new solution addresses mobile expertise challenges within a fleet's business, while promoting consistency, increasing productivity, eliminating multi-vendor sourcing, and providing quick replacement of driver tablets when needed.
  • Omnitracs today announced a new all-in-one fully configured mobile device solution for Omnitracs One.
  • "This new solution was created directly from customer feedback and the market's need to simplify launching and supporting mobile devices in the field," said Mick Milnark, Vice President, Product Management, Omnitracs.

MAKO Medical Prepared to Detect Omicron Variant

Retrieved on: 
Tuesday, November 30, 2021
American, Applied Biosystems, CAP, Veterans Day, Technology, Hospital, PCR, Partnership, Severe acute respiratory syndrome coronavirus 2, Veteran, American City Business Journals, Korea Disease Control and Prevention Agency, COVID-19, Thermo Fisher Scientific, K-12, Omicron, Physician, Workplace, COVID-19 testing, Risk, GLOBE, Real-time, Forbes, RT, Polymerase chain reaction, N, CDC, MAKO, Center, Pharmaceutical industry, Vaccine, Animal, Medical device

Raleigh, North Carolina, Nov. 30, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories , a national reference laboratory and leader in COVID-19 testing, today announced preparedness to detect the potential emergence of the Omicron Variant, with significant available capacity for sequencing and PCR testing.

Key Points: 
  • Raleigh, North Carolina, Nov. 30, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories , a national reference laboratory and leader in COVID-19 testing, today announced preparedness to detect the potential emergence of the Omicron Variant, with significant available capacity for sequencing and PCR testing.
  • The qPCR assay our MAKO Medical team deploys checks for all three targets in a COVID-19 positive test result, the N gene, S gene, and ORF1ab, said Josh Arant, Chief Operating Officer, MAKO Medical.
  • Earlier this year, MAKO Medical formed a comprehensive partnership with the Centers for Disease Control and Prevention (CDC) to provide next-generation sequencing of SARS-CoV-2.
  • While we pray the Omicron Variant does not become widespread in the United States, the MAKO team is actively monitoring for it and prepared to report its emergence, said Arant.